Elevation Oncology (ELEV) has released an update to notify the public and investors about its officers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Elevation Oncology, Inc. appointed Darcy Mootz, Ph.D., as a Class II director and member of the Compensation Committee effective immediately, with her term set to expire at the 2026 annual stockholders’ meeting. Dr. Mootz, who declared independent by the Board per SEC and Nasdaq rules, is the current President of Architect Therapeutics and holds a B.S. from Duke and a Ph.D. from Harvard. She has extensive experience in the pharmaceutical industry, including leadership roles at Amunix Pharmaceuticals and ORIC Pharmaceuticals, and sits on the board of Alpha-9 Oncology. Dr. Mootz has been granted an initial stock option, will receive an annual retainer for her board service, and has entered into a standard indemnity agreement with the Company.
For further insights into ELEV corporate activity, check out TipRanks’ Insiders Trading Activity page.